{
    "nct_id": "NCT04972110",
    "official_title": "Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)",
    "inclusion_criteria": "* Male or female and ≥18 years-of-age at the time of signature of the informed consent\n* Confirmed advanced solid tumors resistant or refractory to standard treatment\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* Evaluable disease as per RECIST v1.1\n* Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers.\n* Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible\n* Acceptable hematologic and organ function at screening\n* Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug.\n* Ability to swallow and retain oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.\n* Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10 days or 5 half-lives (whichever is longer), prior to first dose of study drug.\n* Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose of study drug.\n* History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.\n* No other anticancer therapy is to be permitted while the patient is receiving study treatment.\n* Major surgery ≤28 days or minor surgical procedures ≤7 days prior to first study treatment dose.\n* Uncontrolled, symptomatic brain metastases.\n* Uncontrolled high blood pressure\n* History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis\n* Presence of other known active invasive cancers.\n* Pregnant or breastfeeding women.\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol and/or follow-up procedures outlined in the protocol.",
    "miscellaneous_criteria": ""
}